{"id":898479,"date":"2025-10-21T17:04:50","date_gmt":"2025-10-21T21:04:50","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/heron-therapeutics-to-report-third-quarter-2025-financial-results-on-tuesday-november-4-2025\/"},"modified":"2025-10-21T17:04:50","modified_gmt":"2025-10-21T21:04:50","slug":"heron-therapeutics-to-report-third-quarter-2025-financial-results-on-tuesday-november-4-2025","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/heron-therapeutics-to-report-third-quarter-2025-financial-results-on-tuesday-november-4-2025\/","title":{"rendered":"Heron Therapeutics to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">CARY, N.C., Oct.  21, 2025  (GLOBE NEWSWIRE) &#8212; Heron Therapeutics, Inc. (Nasdaq: HRTX) (\u201cHeron\u201d or the \u201cCompany\u201d), a commercial-stage biotechnology company, today announced that the Company will host a conference call and live webcast on Tuesday, November 4, 2025, at 8:30 a.m. ET to report third quarter 2025 financial results and discuss recent business highlights.<\/p>\n<p align=\"justify\">The conference call can be accessed by phone by utilizing the following\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=HUDxM20gdeqM7hbbKfIi0uqKCQ7tXHWVYGDlrFv-BX80zqoPxYiQNy42gZewsjyjmnDoUyC8U_TehJeWEhFgqAXTN9Q6Md_VtWUgcivR7ReSw6-JztdJ1gHaemdEc3gUZlpWEcfKSOGB9FsJ9NyF5ouJgpvJpqD6PN8G53Hqfhg=\" rel=\"nofollow\" target=\"_blank\">registration link<\/a>\u00a0which will provide participants with dial-in details. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The conference call will also be available via webcast under the Investor Relations section of Heron\u2019s website at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=g0fffTHfQ0AimpbueZfL47YiCWlgW6HRV6oVQVw2F0D4op4PNrTBkbNxfO8-oMd2B_WLTUdGPPzE-VnGAgToR3dH4dA5cuCqM6tUVV6vuGAaft4dz85KtFYIPsallL1T13aNHLtNwT-v88-K1NOs5pKMNBKbq2qDtnDK77WahZFStxjPYOAoGK1qX409WeJcbFbMhclPRXK073Z647pYv7gXeHxjc_SNvj4tvtI_EX1te2OA_k_YuUMv0cYfZizTn17XcqqX-nkfLqD1dXPbqfUDJjLD5TxP3PqSW8LFib6iwftqanGxQH0tvyLQfMJm1UPxoxDdBLl18Pd6dtCDoyN2OEyqlmNBo6YyZiCM6wstyBjIe7TFGeDxCDkHNjQq\" rel=\"nofollow\" target=\"_blank\">www.herontx.com<\/a>. An archive of the teleconference and webcast will also be made available on Heron\u2019s website for 60 days following the call.<\/p>\n<p align=\"justify\">\n        <strong>About\u00a0Heron Therapeutics, Inc.<\/strong>\n      <\/p>\n<p align=\"justify\">Heron Therapeutics, Inc.\u00a0is a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care. Our advanced science, patented technologies, and innovative approach to drug discovery and development have allowed us to create and commercialize a portfolio of products that aim to advance the standard-of-care for acute care and oncology patients. For more information, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=g0fffTHfQ0AimpbueZfL4_2t6-EA2xM_3DNctsKsxxgalCxlGoF9YK1ijmW7DRdGxZMzS_-TpwlwkGu6WF8tHjf8DDAp9zEPD5tVzQdEjMA=\" rel=\"nofollow\" target=\"_blank\">www.herontx.com<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Forward-looking Statements<\/strong>\n      <\/p>\n<p align=\"justify\">This news release contains \u201cforward-looking statements\u201d as defined by the Private Securities Litigation Reform Act of 1995. Heron cautions readers that forward-looking statements are based on management\u2019s expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, but are not limited to, risks and uncertainties identified in the Company\u2019s filings with the Securities and Exchange Commission. Forward-looking statements reflect our analysis only on their stated date, and Heron takes no obligation to update or revise these statements except as may be required by law.<\/p>\n<p>\n        <strong>Investor Relations and Media Contact:<\/strong>\n      <\/p>\n<p>Ira Duarte<br \/>Executive Vice President, Chief Financial Officer<br \/>Heron Therapeutics, Inc.<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=NamWUKtTUMbVMXHQLILXzb_hKSwxZylx3JqOTf5YmFIBroEEDJFrCNkX-eh7OLg4h-hwTEBbpCodKod6mRJaFmZei40tdBlCIbSvhplZmNE=\" rel=\"nofollow\" target=\"_blank\">iduarte@herontx.com<\/a><br \/>858-251-4400<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU0OTUxMSM3MjA3MzQ3IzIwMDc1MTI=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZWE1MTQ4MWUtZjY5ZC00MTllLTlhMWEtY2Q5YWFhNGViODg5LTEwMTkwODUtMjAyNS0xMC0yMS1lbg==\/tiny\/Heron-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CARY, N.C., Oct. 21, 2025 (GLOBE NEWSWIRE) &#8212; Heron Therapeutics, Inc. (Nasdaq: HRTX) (\u201cHeron\u201d or the \u201cCompany\u201d), a commercial-stage biotechnology company, today announced that the Company will host a conference call and live webcast on Tuesday, November 4, 2025, at 8:30 a.m. ET to report third quarter 2025 financial results and discuss recent business highlights. The conference call can be accessed by phone by utilizing the following\u00a0registration link\u00a0which will provide participants with dial-in details. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The conference call will also be available via webcast under the Investor Relations section of Heron\u2019s website at\u00a0www.herontx.com. An archive of the teleconference and webcast will &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/heron-therapeutics-to-report-third-quarter-2025-financial-results-on-tuesday-november-4-2025\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Heron Therapeutics to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-898479","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Heron Therapeutics to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/heron-therapeutics-to-report-third-quarter-2025-financial-results-on-tuesday-november-4-2025\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Heron Therapeutics to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CARY, N.C., Oct. 21, 2025 (GLOBE NEWSWIRE) &#8212; Heron Therapeutics, Inc. (Nasdaq: HRTX) (\u201cHeron\u201d or the \u201cCompany\u201d), a commercial-stage biotechnology company, today announced that the Company will host a conference call and live webcast on Tuesday, November 4, 2025, at 8:30 a.m. ET to report third quarter 2025 financial results and discuss recent business highlights. The conference call can be accessed by phone by utilizing the following\u00a0registration link\u00a0which will provide participants with dial-in details. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The conference call will also be available via webcast under the Investor Relations section of Heron\u2019s website at\u00a0www.herontx.com. An archive of the teleconference and webcast will &hellip; Continue reading &quot;Heron Therapeutics to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/heron-therapeutics-to-report-third-quarter-2025-financial-results-on-tuesday-november-4-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-21T21:04:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU0OTUxMSM3MjA3MzQ3IzIwMDc1MTI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/heron-therapeutics-to-report-third-quarter-2025-financial-results-on-tuesday-november-4-2025\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/heron-therapeutics-to-report-third-quarter-2025-financial-results-on-tuesday-november-4-2025\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Heron Therapeutics to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025\",\"datePublished\":\"2025-10-21T21:04:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/heron-therapeutics-to-report-third-quarter-2025-financial-results-on-tuesday-november-4-2025\\\/\"},\"wordCount\":346,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/heron-therapeutics-to-report-third-quarter-2025-financial-results-on-tuesday-november-4-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU0OTUxMSM3MjA3MzQ3IzIwMDc1MTI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/heron-therapeutics-to-report-third-quarter-2025-financial-results-on-tuesday-november-4-2025\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/heron-therapeutics-to-report-third-quarter-2025-financial-results-on-tuesday-november-4-2025\\\/\",\"name\":\"Heron Therapeutics to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/heron-therapeutics-to-report-third-quarter-2025-financial-results-on-tuesday-november-4-2025\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/heron-therapeutics-to-report-third-quarter-2025-financial-results-on-tuesday-november-4-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU0OTUxMSM3MjA3MzQ3IzIwMDc1MTI=\",\"datePublished\":\"2025-10-21T21:04:50+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/heron-therapeutics-to-report-third-quarter-2025-financial-results-on-tuesday-november-4-2025\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/heron-therapeutics-to-report-third-quarter-2025-financial-results-on-tuesday-november-4-2025\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/heron-therapeutics-to-report-third-quarter-2025-financial-results-on-tuesday-november-4-2025\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU0OTUxMSM3MjA3MzQ3IzIwMDc1MTI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU0OTUxMSM3MjA3MzQ3IzIwMDc1MTI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/heron-therapeutics-to-report-third-quarter-2025-financial-results-on-tuesday-november-4-2025\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Heron Therapeutics to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Heron Therapeutics to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/heron-therapeutics-to-report-third-quarter-2025-financial-results-on-tuesday-november-4-2025\/","og_locale":"en_US","og_type":"article","og_title":"Heron Therapeutics to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025 - Market Newsdesk","og_description":"CARY, N.C., Oct. 21, 2025 (GLOBE NEWSWIRE) &#8212; Heron Therapeutics, Inc. (Nasdaq: HRTX) (\u201cHeron\u201d or the \u201cCompany\u201d), a commercial-stage biotechnology company, today announced that the Company will host a conference call and live webcast on Tuesday, November 4, 2025, at 8:30 a.m. ET to report third quarter 2025 financial results and discuss recent business highlights. The conference call can be accessed by phone by utilizing the following\u00a0registration link\u00a0which will provide participants with dial-in details. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The conference call will also be available via webcast under the Investor Relations section of Heron\u2019s website at\u00a0www.herontx.com. An archive of the teleconference and webcast will &hellip; Continue reading \"Heron Therapeutics to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/heron-therapeutics-to-report-third-quarter-2025-financial-results-on-tuesday-november-4-2025\/","og_site_name":"Market Newsdesk","article_published_time":"2025-10-21T21:04:50+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU0OTUxMSM3MjA3MzQ3IzIwMDc1MTI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/heron-therapeutics-to-report-third-quarter-2025-financial-results-on-tuesday-november-4-2025\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/heron-therapeutics-to-report-third-quarter-2025-financial-results-on-tuesday-november-4-2025\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Heron Therapeutics to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025","datePublished":"2025-10-21T21:04:50+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/heron-therapeutics-to-report-third-quarter-2025-financial-results-on-tuesday-november-4-2025\/"},"wordCount":346,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/heron-therapeutics-to-report-third-quarter-2025-financial-results-on-tuesday-november-4-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU0OTUxMSM3MjA3MzQ3IzIwMDc1MTI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/heron-therapeutics-to-report-third-quarter-2025-financial-results-on-tuesday-november-4-2025\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/heron-therapeutics-to-report-third-quarter-2025-financial-results-on-tuesday-november-4-2025\/","name":"Heron Therapeutics to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/heron-therapeutics-to-report-third-quarter-2025-financial-results-on-tuesday-november-4-2025\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/heron-therapeutics-to-report-third-quarter-2025-financial-results-on-tuesday-november-4-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU0OTUxMSM3MjA3MzQ3IzIwMDc1MTI=","datePublished":"2025-10-21T21:04:50+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/heron-therapeutics-to-report-third-quarter-2025-financial-results-on-tuesday-november-4-2025\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/heron-therapeutics-to-report-third-quarter-2025-financial-results-on-tuesday-november-4-2025\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/heron-therapeutics-to-report-third-quarter-2025-financial-results-on-tuesday-november-4-2025\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU0OTUxMSM3MjA3MzQ3IzIwMDc1MTI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU0OTUxMSM3MjA3MzQ3IzIwMDc1MTI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/heron-therapeutics-to-report-third-quarter-2025-financial-results-on-tuesday-november-4-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Heron Therapeutics to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/898479","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=898479"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/898479\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=898479"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=898479"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=898479"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}